The Discovery of Vasopressin
| Category | Research |
|---|---|
| Also known as | ADH discovery, antidiuretic hormone history, arginine vasopressin history |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | historyvasopressinADHpituitarywater-balance |
Overview
Vasopressin, also known as antidiuretic hormone (ADH) or arginine vasopressin (AVP), is a nine-amino-acid peptide synthesized in the hypothalamus and released from the posterior pituitary. It regulates water balance by reducing urine volume, contributes to blood pressure control through vasoconstriction, and acts as a neuromodulator in the central nervous system.
The vascular effects of pituitary extracts were first described in the 1890s by George Oliver and Edward Albert Schäfer in the United Kingdom, who noted that injection of extracts caused marked rises in blood pressure. Henry Dale and others subsequently characterized additional effects on uterine contraction and water retention. Oliver Kamm, working at Parke-Davis in 1928, separated vasoconstrictor and uterotonic activities, showing that pituitary extracts contain two distinct active principles — the molecules eventually known as vasopressin and oxytocin.
The full structure of arginine vasopressin was determined in the early 1950s, and Vincent du Vigneaud's laboratory completed its chemical synthesis in 1954, shortly after the landmark synthesis of oxytocin. The two peptides differ by only two amino acids, yet have distinct physiological roles, making them a classic example of how small sequence differences can encode very different biological activities.
Key People
- George Oliver and Edward Albert Schäfer: Described vasoconstrictor activity of pituitary extracts in 1895.
- Henry H. Dale (1875–1968): British pharmacologist who characterized uterine and blood pressure effects.
- Oliver Kamm: Parke-Davis chemist who separated vasopressin and oxytocin activities in 1928.
- Vincent du Vigneaud (1901–1978): Synthesized vasopressin in 1954.
Timeline
- 1895: Oliver and Schäfer describe pressor effects of pituitary extracts.
- 1906: Dale describes uterotonic activity.
- 1913: Farini and von den Velden independently report antidiuretic effects in diabetes insipidus.
- 1928: Kamm separates vasopressin from oxytocin.
- 1951: Amino acid composition of vasopressin is determined.
- 1953: Oxytocin synthesis is published.
- 1954: Synthesis of vasopressin is published.
- 1964: The diabetes insipidus-related vasopressin analog desmopressin is synthesized.
- 1992: Vasopressin V1a, V1b, and V2 receptors are cloned.
Background
Vasopressin has three main receptor subtypes: V1a, V1b, and V2. V1a receptors mediate vascular smooth muscle contraction. V1b receptors are expressed in the anterior pituitary and mediate ACTH release. V2 receptors are concentrated in the renal collecting duct and, when activated, increase water permeability by inserting aquaporin-2 channels into the luminal membrane. This last pathway accounts for vasopressin's antidiuretic role.
The peptide's synthesis in magnocellular neurons of the supraoptic and paraventricular nuclei of the hypothalamus, its transport along axons to the posterior pituitary, and its pulsatile release in response to osmotic and volume stimuli provided a foundational example of neurosecretion — the idea that neurons can secrete hormones directly into the bloodstream. This concept, championed by Wolfgang Bargmann and Ernst Scharrer, reshaped mid-20th-century endocrinology.
Modern Relevance
Vasopressin and its analogs are widely used in clinical medicine. Desmopressin is a selective V2 agonist used for central diabetes insipidus, nocturnal enuresis, and mild hemophilia A or von Willebrand disease. Terlipressin is a longer-acting V1 agonist used for variceal bleeding and hepatorenal syndrome. V2 receptor antagonists ("vaptans") such as tolvaptan are used in hyponatremia and polycystic kidney disease.
Vasopressin also plays a growing role in neuropsychiatric research. It modulates social behavior, pair bonding, aggression, and anxiety, often in concert with oxytocin. These findings have spurred interest in selective V1a and V1b antagonists for anxiety, depression, and autism-related social deficits.
Related Compounds
Related entries
- Du Vigneaud and the Synthesis of Oxytocin— In 1953, Vincent du Vigneaud synthesized oxytocin, the first biologically active peptide hormone made entirely in the laboratory.
- The First Synthetic Oxytocin— Synthetic oxytocin, first produced by du Vigneaud in 1953, was the first peptide hormone to be assembled in the laboratory and used clinically.
- The Discovery of Somatostatin— Somatostatin, the hypothalamic peptide that inhibits growth hormone release, was identified in 1973 by Brazeau and Guillemin.